Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

Differentiating palliative care from hospice is crucial; palliative care focuses on holistic treatment, while hospice ...

Separate facts and misconceptions about ovarian cancer to help better prevent and manage the disease.

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

Corcept Therapeutics, a pharmaceutical company specialising in cortisol-modulating medications, has announced that its ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian cancer by nearly 80 per cent. The strategy, known as opportunistic ...

Investigators compared the efficacy and safety of suvemcitug plus chemotherapy vs chemotherapy plus placebo for patients with platinum-refractory or resistant ovarian cancer.

A special first birthday celebration was held at the Daegu Cha Hospital Infertility Center on the 20th. The protagonists were ...